StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
DGXBullishEarningsnews
High materiality9/10

Quest Diagnostics beats Q2, raises guidance; DGX rally strengthens

Jul 23, 2026, 2:06 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Strong quarterly beat, raised guidance, and a slide to new highs signal near-term upside potential; favorable volume mix from partnerships supports earnings durability, suggesting multiple expansion risk is skewed to the upside.

AI summary

What happened, with direct paths to the underlying reporting

Quest Diagnostics delivered a solid Q2 with adjusted EPS of $3.12 and revenue of $3.043 billion, up 10.2% year over year and 10% organically. Broad demand across physician, hospital and consumer channels, plus partnerships with Corewell Health and Fresenius, buoyed volumes and lifted full-year guidance to 2026 targets. The results support a bullish near-term setup for DGX, assuming demand remains resilient and the volume mix stays favorable.

  • Q2 adjusted EPS $3.12 vs $2.83 est; revenue $3.043B, +10.2%.
  • Organic revenue up 10%; demand across physicians, hospitals and consumers.
  • Total requisition volume +13.1%; partnerships contributed about 9% of total.
  • Guidance raised: EPS $11.05-$11.25; revenue $11.95B-$12.05B. Above Wall Street estimates.
  • DGX up 6.14%, trading at a new 52-week high.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event